Mode
Text Size
Log in / Sign up
N/A N=10 Randomized Treatment

Acupuncture for Nasal Congestion in Allergic Rhinitis

Allergic Rhinitis

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Acupuncture (Other); Antihistamine nasal spray (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johanna Maria Vermeulen
Primary completion
Nov 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value)
-8; -2

Summary

Allergic rhinitis (AR) is a disorder that affects more than 500 million people worldwide. Nasal congestion is one of the most general and bothersome symptoms in rhinitis, which impacts the quality of life (QOL). Current medications are undesirable due to their side-effects and there are AR patients who perceive inadequate responses despite to advancements in conventional medicine. Acupuncture for AR in general can be considered as safe and can be seen as a potential therapeutic intervention for nasal congestion. Evidence supported that acupuncture is clinically used for signs and symptoms of nose disorders, such as nasal congestion, with effectiveness, but whether acupuncture has immediate, post-treatment and long-term effects on nasal congestion in AR is not verified by strictly designed clinical study. The ANCAR trial uses a standard treatment protocol with a fixed set of acupuncture points - to be as scientific as possible from Western medical viewpoint - to open the nose and affect underlying energetic imbalance and immunity at the same time, to maintain its nose opening effect. This novel acupuncture treatment protocol can be seen as a solid and profound approach from which every AR patient may benefit.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed AR by a physician
  • Have one of the AR types: seasonal (SAR) or perennial (PAR) or mixed (MAR) allergic rhinitis
  • VAS nasal congestion: 3-10
  • Age: from 18 years
  • Signed Informed Consent

Exclusion Criteria

  • COVID-19
  • Acute common cold
  • Influenza
  • Fever (38°C or higher)
  • Acute nasal trauma (such as a fracture and epistaxis)
  • Irreversible nasal blockages (such as septum deviation, concha bullosa, polyps and cysts)
  • Nasal and sinus cancer
  • Pregnancy or planning for pregnancy
  • Consumed decongestions, antihistamines, antibiotics or corticosteroids within 2 weeks before the RCT
  • Received acupuncture, Chinese herbal medicine or another complementary treatment within 2 weeks before the RCT
  • Received immunotherapy within 2 weeks before the RCT
  • Participants refusing or unable to sign Informed Consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05709977). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search